CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED 【For Immediate Release】
中國神威藥業集團有限公司
China Shineway Pharmaceutical Group Ltd.（Stock code: 2877）
China Shineway Announces Annual Results Net Profit Reached RMB705 million Proposed Final and Special Dividend Totaling RMB22 Cents per Share Financial HighlightsRMB | For the Year Ended 31 December | ||
RMB | 2014 | 2013 | Changes |
Turnover (Million) | 2,229 | 2,187 | 1.9% |
Profit for the Year (Million) | 705 | 684 | 3.1% |
Basic and Diluted Earnings per share (RMB cents) | 85 | 83 | 2.4% |
Final Dividend per Share (RMB cents) | 12 | 12 | - |
Special Dividend per Share (RMB cents) | 10 | 10 | - |
RMB (Million) | For the Year Ended 31 December 2014 | ||
RMB (Million) | Sales | Growth Rate | Product Mix |
Injections | 1,348 | 0.9% | 60.4% |
Soft Capsules | 446 | 1.9% | 20.0% |
Granules | 357 | 4.6% | 16.0% |
Other Product Formats | 78 | 7.7% | 3.6% |
(Hong Kong, 27 March 2015) ---- The largest Chinese medicine injection, soft capsule and granule manufacturer, China Shineway Pharmaceutical Group Limited ("China Shineway"), and collectively with its subsidiaries ("the Group") (SEHK code: 2877) today announced its annual results for the year ended 31
December 2014, of which, the Group recorded a turnover of approximately RMB2,229 million representing an increase of approximately 1.9% as compared to last year (2013: approximately RMB2,187 million). Profit for the year increased by approximately 3.1% to approximately RMB705 million from approximately RMB684 million from last year. Basic and diluted earnings per share were approximately RMB85 cents (2013: approximately RMB83 cents). The bank balances and cash was recorded at approximately RMB2,688.1 million (2013: approximately RMB2,291.9 million) as at 31 December 2014.
The Board of Directors proposed to declare a final dividend of RMB12 cents per share (2013: RMB12 cents) and a special dividend of RMB10 cents per share (2013: RMB10 cents) for the year ended 31 December 2014. In addition to the interim dividend of RMB11 cents per share already paid, the dividend for the full year amounted to RMB33 cents per share (2013: RMB33 cents).
2014 was an important year of development for China Shineway. We adjusted our infrastructure, reconsolidated our resources, coped with changes and the group established a solid foundation and continued our innovation development in 2014."
~Page 1 of 3~
China Shineway Pharmaceutical Group Limited
27 March 2015 / Page 2/3
During the year under review, China Shineway's new injection workshop has gained its new GMP certification and commenced production while the new extraction workshop has completed its testing stage and started production. The Group sold approximately RMB1,348 million of injection products, an increase of approximately 0.9% from year 2013, accounted for approximately 60.4% (2013: approximately 61.0%) of the Group's turnover in 2014. Qing Kai Ling Injection, the Group's main product, took up a major proportion of the total turnover. There are continued market demands for Chinese medicine injection products. The Group's annual production capacity for injection product is now approximately 3.2 billion vials. The Group believes that it is currently the largest Chinese medicine injections manufacturer in the PRC in terms of sales volume and production capacity. A number of the Group's injection products are designated by regulatory agencies as "Good Quality/Good Price" products.
During the year, the Group recorded approximately RMB446 million on sales of soft capsule products, an increase of approximately 1.9% from last year. The increase was mainly driven by the increased sales of Huo Xiang Zheng Qi Soft Capsule and Compound Trivitamin and Linolic Acid Soft Capsule I. Soft Capsule products accounted for approximately 20.0% of the Group's turnover in 2014, as compared to approximately 20.0% in last year. The Group's current production capacity for soft capsules is 3.5 billion capsules per annum. The Group believes that it is currently the largest Chinese medicine soft capsules manufacturer in the PRC in terms of sales volume and production capacity.
Sales of granule products in 2014 increased by approximately 4.6%, amounted to approximately RMB357 million. This was mainly attributable to the year-on-year sales increase of Pediatric Qing Fei Hua Tan Granule and Liyan Jiedu Granule. Granule products accounted for approximately 16.0% of the Group's turnover in
2014 as compared to approximately 15.6% in 2013. The Group's new granule and tablet workshop commenced production in previous year with annual production capacity for granule products of approximately 3.4 billion bags per annum. The Group believes that it is currently the largest Chinese medicine granules manufacturer in PRC in terms of sales volume and production capacity.
Sales of other products in 2014 increased by approximately 7.7% compared to last year, amounted to approximately RMB78 million. The increase was mainly attributable to the rise in sales of Xuesaitong Diwan and the ointment products as compared with last year. The six key products of the Group were Qing Kai Ling Injection, Shen Mai Injection, Shu Xie Ning Injection, Wu Fu Xin Nao Qing Soft Capsule, Huo Xiang Zheng Qi Soft Capsule and Pediatric Qing Fei Hua Tan Granule.
China Shineway's innovation research and development system achieved significant achievement in 2014. The Group had 14 new projects during the year. There were 16 patent applications. Projects under research and development covered Chinese medicine, chemical drugs, biochemical drugs and healthcare products.
The research work on the preparing technology and quality standard required by the State Administration of Traditional Chinese Medicine has been completed for over 600 kinds of prescriptive Chinese medicine granules which are also eligible to be used clinically by medical units above the county level in Hebei Province that will be a new growth point of the business. The Group will continue to extend new areas for prescriptive Chinese medicine granules.
In 2014, the Group's Chinese medicine extraction capacity has increased to 20,000 tons. The Group will strengthen and diversify the Chinese medicine product line, actively seek and merge those Chinese medicine products with market potential, and build series of product groups of tumour medicines, cardiovascular medicines, diabetes medicines, anti-viral medicines and gynecological drugs, etc. It will also seek good strains, diversify chemical drug product chains, realise the development and production of the chemical drug, and gradually expand its sales scale, with expectation of effectively supplement the sales business of the Chinese medicine.
~Page 2 of 3~
China Shineway Pharmaceutical Group Limited
27 March 2015 / Page 3/3
Mr. Li Zhenjiang, Chairman of the Group concluded, "Looking forward, the medical industry development will be full of opportunities and challenges. We focus on our main business of modern Chinese medicine, positively copes with policy changes, strengthens the terminal network construction, improves the control of terminals; speeds up R&D and merger matters, adjusts the products structure; accelerates the construction of talents team, improves the professional capacity of employees, creates a positive organizational atmosphere, stimulates the innovation energy of employees; promotes outstanding performance, enhances the operation and management ability. Basing on the brand effectiveness and mature marketing network and scientific research innovation strength, the Group will try to realise a maximization in the efficiency of marketing value chain through making new products available continuously in the market and striving to innovate patterns and improve marketing ability, to ensure the achievement of strategic target of our Group, and to bring the maximum interest and return for its shareholders."~End~
About China Shineway Pharmaceutical Group Limited (Stock Code: 2877)
China Shineway Pharmaceutical Group Limited is one of the largest modern Chinese medicines manufacturers in the PRC. The Group is listed on the Main Board of Hong Kong Stock Exchange and is also a Hang Seng Composite Index constituent. After the "Shineway" trademark was named as China Famous Trademark in
2002, our "Wu Fu" trademark and "Shen Miao" trademark were subsequently identified as China Famous Trademarks. We became the first one in Hebei Province having three China Famous Trademarks. In addition, our "Bei Si" and " Zhikeping" trademark were also awarded as Hebei Province Famous Trademark.
Jovian Communication │ Angel Yeung │ Tel：(852) 2581 0168 │shineway@joviancomm.com
|
distributed by
|
